AVITA Medical, Inc. (NASDAQ:RCEL) CFO David D. O’toole Acquires 1,000 Shares of Stock

AVITA Medical, Inc. (NASDAQ:RCEL) CFO David D. O’toole bought 1,000 shares of the firm’s stock in a transaction on Wednesday, February 19th. The shares were purchased at an average price of $10.25 per share, for a total transaction of $10,250.00. Following the purchase, the chief financial officer now owns 24,734 shares in the company, valued at $253,523.50. This trade represents a 4.21 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

AVITA Medical Stock Performance

Shares of NASDAQ RCEL opened at $10.22 on Thursday. The company has a market cap of $267.97 million, a P/E ratio of -4.28 and a beta of 1.55. AVITA Medical, Inc. has a 52-week low of $7.51 and a 52-week high of $18.93. The company has a debt-to-equity ratio of 9.39, a quick ratio of 2.47 and a current ratio of 2.83. The firm’s fifty day moving average is $10.51 and its two-hundred day moving average is $10.62.

AVITA Medical (NASDAQ:RCEL) last issued its earnings results on Thursday, February 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.14). AVITA Medical had a negative return on equity of 337.91% and a negative net margin of 96.26%. The firm had revenue of $18.41 million during the quarter, compared to the consensus estimate of $18.40 million. As a group, analysts anticipate that AVITA Medical, Inc. will post -1.3 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of AVITA Medical in a research note on Friday, February 14th. Piper Sandler reiterated a “neutral” rating and issued a $12.00 price target (up previously from $9.00) on shares of AVITA Medical in a research note on Friday, November 8th. Lake Street Capital lowered their price objective on AVITA Medical from $20.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 target price on shares of AVITA Medical in a research report on Tuesday, December 24th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Huntington National Bank purchased a new stake in AVITA Medical during the third quarter valued at $32,000. BNP Paribas Financial Markets bought a new stake in shares of AVITA Medical in the 4th quarter worth about $38,000. FMR LLC increased its holdings in shares of AVITA Medical by 126.9% in the 3rd quarter. FMR LLC now owns 4,248 shares of the company’s stock worth $46,000 after buying an additional 2,376 shares during the last quarter. Quest Partners LLC raised its position in shares of AVITA Medical by 269.4% during the 3rd quarter. Quest Partners LLC now owns 7,520 shares of the company’s stock valued at $81,000 after buying an additional 5,484 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of AVITA Medical by 48.0% in the 4th quarter. Russell Investments Group Ltd. now owns 7,164 shares of the company’s stock valued at $92,000 after acquiring an additional 2,324 shares during the last quarter. 27.66% of the stock is currently owned by institutional investors.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.